Table 3.
Summary of patient responses
| Patient | Gender | Cancer type | Established valproic acid serum level (µg/ml) | Best response | Time to progression (weeks) | Site of progression | ATRA-IV dose (mg/m2) | Number of cycles completed |
| 1 | M | Renal cell carcinoma | 50–80 | POD | 8 | Brain/bone/lung | 60 | 2 |
| 2 | M | Bladder urothelial carcinoma | 50–80 | POD | 7 | Lung | 60 | 1.75 |
| 3 | M | Renal cell carcinoma | -a | - | - | - | - | 0b |
| 4 | M | Gastroesophageal adenocarcinoma | 50–80 | Deathc | 4 | - | 60 | 1 |
| 5 | M | Mesothelioma | -a | - | - | - | - | 0d |
| 6 | M | Prostate adenocarcinoma | 80–100 | SD | 16 | PSA progression | 60 | 4 |
| 7 | M | Sarcoma | 80–100 | POD | 6 | Bone | 60 | 1.5 |
| 8 | M | Bladder urothelial carcinoma | -a | - | - | - | - | 0e |
| 9 | M | Prostate adenocarcinoma | -a | - | - | - | - | 0f |
One cycle of therapy lasts 4 w.
a
Patient did not establish a serum concentration of valproic acid within the expected range. Patient not evaluable for response.
b
Patient developed grade 2 allergic skin rash one day following initiation of Depakote.
c
Patient expired after 5 w on study due to airway obstruction related to progression of disease.
d
Patient developed grade 2 allergic skin rash two days following initiation of Depakote.
e
Patient was taken off study after 2 w due to recurrent intermittent grade 2 headache.
f
Patient developed grade 4 right lower extremity paralysis possibly related to epidural disease. POD, progression of disease; SD, stable disease.